Short answer
Syndax Pharmaceuticals Inc (SNDX) filed its Q2 2026 10-Q quarterly report on Aug 4, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $73M (up 93.0% year over year) with net income of −$49M.
Q2 2026 key financials · XBRL
- Revenue
- $73M
- +93.0% YoY · +12.2% QoQ
- Net income
- −$49M
- +31.3% YoY · −15.7% QoQ
- Operating margin
- -54.9%
- EPS (diluted)
- −$0.56
- +33.3% YoY · −16.7% QoQ
Source: XBRL data from the Syndax Pharmaceuticals Inc (SNDX) Q2 2026 10-Q on SEC EDGAR. USD.
Syndax Pharmaceuticals Inc Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New $250.0 million indebtedness risk triggered by June 2026 issuance of 2031 Notes
- Conversion or fundamental-change repurchases could require cash unavailable to Syndax
- Conditional convertibility could reclassify notes as current liabilities, materially reducing working capital
- Noteholder conversion could pressure liquidity through required cash settlement
- Convertible-note accounting increases interest expense beyond cash interest payments
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Syndax Pharmaceuticals Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.